Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Drug firm Morepen Laboratories on Thursday said its consolidated net profit declined by 55 per cent to Rs 12 crore for the fourth quarter ended March 2022.

Morepen Q4: Net profit falls 55% to Rs 12 cr, total income up to Rs 371 cr

Elecon Engineering Company Ltd, Borosil Renewables Ltd, Laxmi Organic Industries Ltd and Geojit Financial Services Ltd are among the other losers in the BSE’s ‘A’ group today, 05 May 2022.

Morepen Laboratories Ltd leads losers in ‘A’ group

The drug maker had reported a net profit of Rs 23.79 crore in the same period of previous fiscal year.

Morepen Laboratories Q3 Results | Profit dips 10% to Rs 22 crore

Morepen Laboratories jumps 7.6%  up most in more than 7 months company receives the u.s. Fda approval for its anti-allergy drug fexofinadine hydrochloride, which is marketed in india under the brand name allegra; expects to start export in 4qfy22

Eris lifesciences advances 3% the pharma company plans to set up a 10-year joint venture with mj biopharm to enter the insulin market. Eris will hold a 70% stake in the joint venture, which will primarily engage in the marketing and distribution of human and analogue insulins, including glargine, aspart and lispro, among other biopharma products in india. 
Inox wind energy: Co has informed the exchange regarding 'proposed initial public offering of equity shares of face value of rs. 10 each ( equity shares ) by the cos material subsidiary, Inox green energy services

BCL up 6%  co has been been allocated quantity of 3.60 cr litres of ethanol from our manufacturing unit at bathinda for supplies to OMCs 

Vodafone idea up 6% 
Gains for the 3rd consecutive day 
Files application with govt for settlement of retro tax dispute
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Morepen Laboratories, Eris lifesciences & Others | Midday Movers

Morepen Laboratories jumped 11.98% to Rs 58.90, extending gains for the third consecutive session.

Morepen Lab spurts over 17% in three sessions

Indo Count Industries Ltd, Hindustan Construction Company Ltd, Privi Speciality Chemicals Ltd and Vodafone Idea Ltd are among the other gainers in the BSE’s ‘A’ group today, 06 December 2021.

Morepen Laboratories Ltd leads gainers in ‘A’ group

Morepen’s product is the generic version of Sanofi Aventis’ anti- allergy drug.

Morepen Laboratories gets USFDA nod to market generic anti-allergy drug

Drug firm Morepen Laboratories on Friday said it has received approval from the US health regulator to market its anti-allergy drug Fexofinadine in the American market.

Morepen gets USFDA nod to market generic anti-allergy drug

Fexofinadine is most widely used, second generation antihistamine drug for the treatment of allergy symptoms and hay fever.

Morepen Laboratories receives USFDA approval for Fexofinadine Hydrochloride (Allegra)

Bharat Dynamics Ltd, Raymond Ltd, Morepen Laboratories Ltd and Elgi Equipments Ltd are among the other gainers in the BSE’s ‘A’ group today, 29 November 2021.

BEML Ltd leads gainers in ‘A’ group

“With massive increase in active pharmaceutical ingredient (API) demand globally and more particularly with frequent supply disruptions from China, we are putting our expansion plans for API on fast track,” Morepen Laboratories Chairman and MD Sushil Suri said.

Morepen Labs Q2 results: Net profit up 38% at Rs 37 crore

Morepen Laboratories Limited is a pharmaceutical company. The Company operates through four segments; they are Active Pharmaceutical Ingredients (API), Domestic Formulations, Diagnostics and Over the Counter (OTC).

Morepen Laboratories Ltd

Morepen Laboratories Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Morepen Q4: Net profit falls 55% to Rs 12 cr, total income up to Rs 371 cr

Morepen Laboratories Ltd leads losers in ‘A’ group

Morepen Laboratories Q3 Results | Profit dips 10% to Rs 22 crore

News Video

Morepen Laboratories, Eris lifesciences & Others | Midday Movers

Morepen Lab spurts over 17% in three sessions

Morepen Laboratories Ltd leads gainers in ‘A’ group

Morepen Laboratories gets USFDA nod to market generic anti-allergy drug

Morepen Laboratories Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Morepen Q4: Net profit falls 55% to Rs 12 cr, total income up to Rs 371 cr

Morepen Laboratories Ltd leads losers in ‘A’ group

Morepen Laboratories Q3 Results | Profit dips 10% to Rs 22 crore

News Video

Morepen Laboratories, Eris lifesciences & Others | Midday Movers

Morepen Lab spurts over 17% in three sessions

Morepen Laboratories Ltd leads gainers in ‘A’ group

Morepen Laboratories gets USFDA nod to market generic anti-allergy drug

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock